Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Resistance to anti-HIV drugs in steep decline in Switzerland

Prevalence of antiretroviral drug resistance has declined significantly among patients in Switzerland, investigators report in the online edition of Clinical Infectious Diseases. As many as 57% of

Published
13 April 2016
By
Michael Carter
HIV took just 2 weeks to overcome our best attempt to edit it out of our cells

We all got really excited a few weeks ago when researchers announced they'd removed HIV from human immune cells using new gene-editing technology called CRISPR/Cas-9, or 'CRISPR' for short, which works like a pair of molecular scissors to cut and paste DNA. As far as we know, that specific result is holding up just fine, but a separate study has now revealed that, worryingly, HIV can evolve to survive CRISPR attacks in just two weeks. Even worse, the attack itself could actually be introducing mutations that make the virus stronger.

Published
11 April 2016
From
ScienceAlert
VRC01 antibody delays but does not prevent HIV rebound after antiretroviral treatment interruption

VRC01, a broadly neutralising antibody targeting HIV's CD4 binding site, was able to modestly delay the return of viral replication following interruption of antiretroviral therapy (ART), according to

Published
08 April 2016
By
Liz Highleyman
More people with HIV are achieving viral suppression in US, but about 40% remain above transmission thresholds

A growing proportion of people with HIV are reaching an undetectable viral load on antiretroviral therapy (ART), according to a pair of studies from the US Centers

Published
07 April 2016
By
Liz Highleyman
Media Outlets Falsely Claim That a Cure for HIV May Be Only Three Years Away

A series of media outlets have erroneously reported that scientists may be just three years away from developing a cure for HIV. This false claim traces to an article published in the United Kingdom’s The Telegraph concerning researchers who recently succeeded in editing HIV’s genetic code out of immune cells in a laboratory setting.

Published
06 April 2016
From
Poz
U.S. Food and Drug Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide), Gilead’s Third TAF-Based HIV Therapy

-Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg, F/TAF), a fixed-dose combination for the treatment of HIV. Descovy is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. Descovy is not indicated for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk.

Published
05 April 2016
From
Gilead press release
No adverse social consequences from early ART initiation in West Africa

Early initiation of antiretroviral therapy (ART) does not have negative social consequences, investigators report in the online edition of AIDS. Research involving patients in Côte d’Ivoire showed

Published
05 April 2016
By
Michael Carter
African women in London with poor adherence feel that HIV treatment is difficult and unrelenting

A qualitative study with West African women living in London who have difficulties adhering to their HIV treatment has found that many think of HIV treatment as

Published
04 April 2016
By
Roger Pebody
Long-acting oral antiretroviral MK-8591 could represent 'paradigm shift' in HIV treatment and prophylaxis

An investigational antiretroviral agent that maintains drug levels that are able to inhibit HIV up to six months after dosing could represent a “paradigm shift” in HIV

Published
01 April 2016
By
Michael Carter
Gene therapy snips HIV out of infected cells and makes uninfected cells resistant

For the first time, researchers have used a gene-editing technique already used to produce cells resistant to HIV infection to target HIV-infected cells. They have managed

Published
30 March 2016
By
Gus Cairns

Filter by country